Ph-positive CML – Patient Worthy

The FDA has Issued a Complete Response Letter to Xspray Pharma Delaying Approvals Affecting ALL and CML

Post author:Rose Duesterwald
Post published:November 6, 2025
Post category:Cancer

Xspray Pharma, the developer of the drug dasatinib, was recently issued a Complete Response Letter (CRL) by the FDA while waiting for corrective actions, according to Cancer Network. Based on…

We believe rare disease patients are people, not a diagnosis. Through education, awareness and some humor, we help patients, caregivers and support persons by providing relevant and often inspirational news and stories.

Our goals are to share stories, cultivate strong community, provide the latest medical findings, connect people and pioneer production of patient worthy information. Help us attain these goals by telling us a little bit about yourself!

Let’s Work Together!

Keep Up to Date

Learn More